Insider · CIK 0001831558
Eliot Forster
Files at PLX (Protalix BioTherapeutics, Inc.), IMTX (Immatics N.V.). First filing -, latest -.
Eliot Forster files SEC Form 4 as director at PLX (Protalix BioTherapeutics, Inc.), and also at IMTX (Immatics N.V.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Eliot Forster has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 39 d ago |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 39 d ago |
| Jun 16, 2026 | IMTX Immatics N.V. | AGrant or award Stock Option (Right to Buy)derivative | +48,000 | $0.00 | $0 | 48,000 | Jun 18, 2026 |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
Questions about Eliot Forster
Answered from the filings on this page, as of the latest one.
Is Eliot Forster buying or selling?
Eliot Forster has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Eliot Forster's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Eliot Forster has 0.
Where does Eliot Forster file Form 4?
Eliot Forster has filed Form 4 at PLX (Protalix BioTherapeutics, Inc.); IMTX (Immatics N.V.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.